Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
December 03 2019 - 3:01PM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical
company focused on developing and commercializing new chemical
entities with a primary focus on pruritus by selectively targeting
peripheral kappa opioid receptors, today announced a Company
presentation at the 31st Annual Piper Jaffray Healthcare Conference
on Wednesday, December 4, 2019 at 3:00 p.m. ET in New York, NY.
Earlier today, Cara announced positive topline
results from its Phase 2 dose-ranging trial of Oral KORSUVA™ for
the treatment of pruritus in patients with stage III-V
(moderate-to-severe) chronic kidney disease. Oral KORSUVA met the
primary endpoint of statistically significant reduction in mean
Worst Itching Intensity Numeric Rating Scale (WI-NRS) scores with
the 1 mg tablet strength versus placebo after the 12-week treatment
period (p=0.018). Oral KORSUVA was generally well-tolerated.
A live webcast of the presentation can be
accessed under "Events & Presentations" in the News &
Investors section of the Company's website
at www.CaraTherapeutics.com. An archived webcast recording
will be available on the Cara website for approximately 30
days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors, or KORs. Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that
targets KORs located in the peripheral nervous system, and on
immune cells. In a Phase 3 and two Phase 2 trials, KORSUVA
(CR845/difelikefalin) Injection has demonstrated statistically
significant reductions in itch intensity and concomitant
improvement in pruritus-related quality of life measures in
hemodialysis patients with moderate-to-severe chronic kidney
disease-associated pruritus (CKD-aP), and is currently being
investigated in Phase 3 trials in hemodialysis patients with
CKD-aP. Oral KORSUVA is in Phase 2 trials for the treatment of
pruritus in patients with chronic kidney disease, atopic
dermatitis, and primary biliary cholangitis.
The FDA has conditionally accepted KORSUVA™ as
the trade name for difelikefalin injection. CR845/difelikefalin is
an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
INVESTOR CONTACT:Jane UrheimStern Investor
Relations, Inc. 212-362-1200 jane.urheim@SternIR.com
MEDIA CONTACT:Annie Starr6 Degrees973-415-8838
astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2024 to May 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From May 2023 to May 2024